In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
21 authors.
Inés Muela-ZarzuelaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-7240-8334 Elisabet Alcocer-GómezDepartamento de Psicología Experimental, Facultad de Psicología, Universidad de Sevilla, 41009 Seville, Spain.ORCID 0000-0001-9799-431X Juan M Suarez-RiveroDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-6260-7284 Evon LowBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-4978-5123 Abbas IshaqBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0001-6344-466X Mikel AzkargortaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), CIBERehd, Derio, Spain.ORCID 0000-0001-9115-3202 Amparo Luque-SierraAndalusian Center of Molecular Biology and Regenerative Medicine-CABIMER, University Pablo Olavide-University of Seville-CSIC, Seville, Spain.ORCID 0000-0002-9090-3048 Franz MartinAndalusian Center of Molecular Biology and Regenerative Medicine-CABIMER, University Pablo Olavide-University of Seville-CSIC, Seville, Spain.
Félix ElortzaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), CIBERehd, Derio, Spain.ORCID 0000-0001-8839-5438 Antonio Astorga-GamazaDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0002-1276-5276 Rosa AntónInstituto de Química Física Blas Cabrera (IQF), CSIC, E-28006 Madrid, Spain.
Sofía BaliMolecular Biophysics Graduate Program, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Joaquin Tamargo-AzpilicuetaInstitute for Chemical Research, cicCartuja, University of Seville-CSIC, Seville, Spain.ORCID 0000-0001-8504-4472 Alejandra Guerra-CastellanoInstitute for Chemical Research, cicCartuja, University of Seville-CSIC, Seville, Spain.ORCID 0000-0001-5823-1678 Irene Díaz-MorenoInstitute for Chemical Research, cicCartuja, University of Seville-CSIC, Seville, Spain.ORCID 0000-0002-5318-7644 Lukasz A JoachimiakCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.ORCID 0000-0003-3061-5850 Jesús Ruiz-CabelloCIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo de Miramon 182, 20014 Donostia San Sebastián, Spain.ORCID 0000-0001-8681-5056 Thomas von ZglinickiBiosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Alberto SanzSchool of Molecular Biosciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.ORCID 0000-0003-2149-1753 Mario D CorderoDepartment of Molecular Biology and Biochemical Engineering, Universidad Pablo de Olavide, 41013 Seville, Spain.ORCID 0000-0003-0151-3644 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The NLRP3 inflammasome has been implicated in a wide range of human diseases, including cardiovascular, metabolic, neurodegenerative (such as Alzheimer's disease), and other age-related conditions. This has positioned NLRP3 as a promising pharmacological target. Numerous studies have shown that complete NLRP3 ablation can prevent or mitigate these diseases. However, total elimination of NLRP3 is not a feasible therapeutic strategy for the millions of patients affected by these degenerative disorders. Consequently, drug development efforts have focused on partial inhibition of NLRP3 using compounds that reduce its expression or activity. Paradoxically, although many studies have used
Indexed as
Adaptor Proteins, Signal TransducingAgingApoptosis Regulatory ProteinsHaploinsufficiencyNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsInflammasomesInflammationMiceMice, KnockoutNLR ProteinsAdaptor Proteins, Signal TransducingApoptosis Regulatory ProteinsInflammasomesNALP1 protein, mouseNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseNLR Proteins
Identifiers
PMID42361162
PMCPMC13308588
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390